Shineco, Inc. Announces Entering Into a Securities Purchase Agreement with GHS Investments, LLC with Gross Proceeds of $2.0 Million USD

Rhea-AI Summary

Shineco, Inc. (NASDAQ: SISI) has entered into a securities purchase agreement to sell $2 million of its common stock at a price of $6.8546 per share to GHS Investments, LLC. The net proceeds will be utilized for acquiring biotech research companies, working capital, and general corporate purposes. This offering is conducted under an effective shelf registration statement with the SEC. Shineco is focused on producing Chinese herbal medicines and organic agricultural products, headquartered in Beijing.

Positive

• Secured $2 million in gross proceeds through a stock sale.
• Funds will be used for acquiring biotech research companies, potentially enhancing growth.

Negative

• Dilution risk for existing shareholders due to the issuance of new common stock.

BEIJING, Dec. 06, 2021 (GLOBE NEWSWIRE) -- Shineco, Inc. (“Shineco” or the “Company”; NASDAQ: SISI), a producer and distributor of Chinese herbal medicines, organic agricultural and other biotech products, announced that it has entered into a securities purchase agreement (the “Agreement”) for the sale of Gross Proceeds US$2.0 million of its registered common stock at a price of $6.8546 per share with GHS Investments, LLC (“GHS”), a leading private investment and management group providing financial solutions for high potential small cap enterprises.

The Company intends to use the net proceeds from this offering to acquire certain biotech research companies as well as for working capital and general corporate purposes at the sole discretion of the Company.

This offering is being made pursuant to an effective shelf registration statement on Form S-3, as amended (File No. 333-250160), which was subsequently declared effective by the U.S. Securities and Exchange Commission (the “SEC”) on June 23, 2021. A prospectus supplement describing the terms of the proposed offering has been filed with the SEC and available on the SEC’s website at http://www.sec.gov.

This press release does not constitute an offer to sell or the solicitation of an offer to buy, nor there any sales of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such jurisdiction.

About Shineco, Inc.

Incorporated in Delaware in August 1997 and headquartered in Beijing, China, Shineco is a holding company. Utilizing modern engineering technologies and biotechnologies, Shineco produces, among other products, Chinese herbal medicines, organic agricultural produce, and specialized textiles. For more information about Shineco, please visit http://tianyiluobuma.com.

Forward-Looking Statements

This press release contains information about Shineco's view of its future expectations, plans and prospects that constitute forward-looking statements. You are cautioned not to place undue reliance on these forward-looking statements. Actual results may differ materially from historical results or those indicated by these forward-looking statements as a result of a variety of factors including, but not limited to, risks and uncertainties associated with its ability to raise additional funding, its ability to maintain and grow its business, variability of operating results, its ability to maintain and enhance its brand, its development and introduction of new products and services, the successful integration of acquired companies, technologies and assets into its portfolio of products and services, marketing and other business development initiatives, competition in the industry, general government regulation, economic conditions, the impact of the COVID-19 pandemic, dependence on key personnel, the ability to attract, hire and retain personnel who possess the technical skills and experience necessary to meet the requirements of its clients, and its ability to protect its intellectual property. Shineco encourages you to review other factors that may affect its future results in its registration statement and in its other filings with the Securities and Exchange Commission. The forward-looking statements in this press release are based on current expectations and Shineco assumes no obligation to update these forward-looking statements except as required by the applicable rules and regulations.

For more information, please contact:

Tina Xiao

Ascent Investor Relations LLC

Phone: +1-917-609-0333

Email: tina.xiao@ascent-ir.com

FAQ

What is the significance of Shineco's recent stock sale?

Shineco's recent stock sale will raise $2 million to fund biotech acquisitions and working capital, which could drive future growth.

How much is Shineco selling its common stock for?

Shineco is selling its common stock at a price of $6.8546 per share.

Who is purchasing the stock from Shineco?

GHS Investments, LLC is the private investment group purchasing $2 million worth of Shineco's common stock.

What will Shineco do with the proceeds from the stock sale?

Proceeds will be used to acquire biotech research companies and for general working capital purposes.

What is Shineco's stock symbol?

Shineco's stock symbol is SISI.